30 Day Trial

FzioMed Reaches Oxiplex 500K Unit Milestone


FzioMed marked the sale of 500,000 units of its Oxiplex® viscoelastic hydrogel worldwide. This is an increase from 400,000 units sold, as reported in July 2015.

Oxiplex is approved for sale in >70 countries ex-U.S., and distributed under brand names of Oxiplex, Oxiplex/SP, MediShield and Interpose. The absorbable gel is applied to neural tissues following spine surgery, making a temporary barrier between adjacent tissues. The gel has been shown in peer-reviewed studies to reduce leg pain, back pain and neurologic symptoms.

Sources: FzioMed, Inc.; ORTHOWORLD Inc.